Tenofovir DF and emtricitabine vs. zidovudine and lamivudine

被引：0
|
作者：
Jenny-Avital, ER [1 ]
机构：
[1] Jacobi Med Ctr, Bronx, NY 10461 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2006年 / 354卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2507 / 2507
页数：1
相关论文
共 50 条
  • [1] Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Gallant, JE
    DeJesus, E
    Arribas, JR
    Pozniak, AL
    Gazzard, B
    Campo, RE
    Lu, B
    McColl, D
    Chuck, S
    Enejosa, J
    Toole, JJ
    Cheng, AK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03): : 251 - 260
  • [2] Is tenofovir plus emtricitabine superior to zidovudine plus lamivudine?
    Gonzalez-Lahoz, J
    [J]. AIDS REVIEWS, 2005, 7 (01) : 63 - 63
  • [3] Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
    Alzate Angel, Juan Carlos
    Duque Molina, Marcela Maria
    Garcia Garcia, Hector Ivan
    [J]. COLOMBIA MEDICA, 2017, 48 (02): : 70 - 81
  • [4] Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study
    Ribera, E.
    Larrousse, M.
    Curran, A.
    Negredo, E.
    Clotet, B.
    Estrada, V.
    Sanz, J.
    Berenguer, J.
    Rubio, R.
    Pulido, F.
    Ferrer, P.
    Alvarez, M. L.
    Arterburn, S.
    Martinez, E.
    [J]. HIV MEDICINE, 2013, 14 (06) : 327 - 336
  • [5] Week 96 analyses of emergent drug resistance from the STaR Study: rilpivirine/emtricitabine/tenofovir DF vs. efavirenz/emtricitabine/tenofovir DF single-tablet regimens
    Porter, D. P.
    Kulkarni, R.
    Fralich, T.
    Miller, M. D.
    White, K. L.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A123 - A123
  • [6] Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine
    Vourvahis, Manoli
    Davis, John
    Langdon, Grant
    Layton, Gary
    Fang, Juanzhi
    Choo, Heng Wee
    Hansson, Arne G.
    Tawadrous, Margaret
    [J]. ANTIVIRAL THERAPY, 2013, 18 (06) : 745 - 754
  • [7] Abacavir-lamivudine and tenofovir-emtricitabine are superior NRTI options for antiretroviral treatment to zidovudine-lamivudine or tenofovir-lamivudine paired with NNRTI
    Yang, W-L
    Kouyos, R.
    Boeni, J.
    Shah, C.
    Yerly, S.
    Klimkait, T.
    Aubert, V.
    Furrer, H.
    Battegay, M.
    Cavassini, M.
    Bernasconi, E.
    Vernazza, P.
    Guenthard, H. F.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A117 - A117
  • [8] Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients
    Berg, Thomas
    Zoulim, Fabien
    Moeller, Bernd
    Trinh, Huy
    Marcellin, Patrick
    Chan, Sing
    Kitrinos, Kathryn M.
    Dinh, Phillip
    Flaherty, John F., Jr.
    McHutchison, John G.
    Manns, Michael
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (04) : 715 - 722
  • [9] Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio
    Martinez, E.
    Ribera, E.
    Clotet, B.
    Estrada, V.
    Sanz, J.
    Berenguer, J.
    Rubio, R.
    Pulido, F.
    Larrousse, M.
    Curran, A.
    Negredo, E.
    Arterburn, S.
    Ferrer, P.
    Alvarez, M. L.
    [J]. HIV MEDICINE, 2015, 16 (06) : 370 - 374
  • [10] Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston community health center
    Mayer, Kenneth H.
    Mimiaga, Matthew J.
    Cohen, Daniel
    Grasso, Chris
    Bill, Ronn
    VanDerwarker, Rodney
    Fisher, Alvan
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (04) : 494 - 499
12345